Letters/Replies
Reply to Suvorexant for Preventing Alzheimer's Disease
Brendan P. Lucey MD, MSCI,
Corresponding Author
Brendan P. Lucey MD, MSCI
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Address correspondence to Dr Brendan P. Lucey, Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO 63110, USA. E-mail: [email protected]
Search for more papers by this author Randall J. Bateman MD,
Randall J. Bateman MD
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Search for more papers by this author
Brendan P. Lucey MD, MSCI,
Corresponding Author
Brendan P. Lucey MD, MSCI
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Address correspondence to Dr Brendan P. Lucey, Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO 63110, USA. E-mail: [email protected]
Search for more papers by this author Randall J. Bateman MD,
Randall J. Bateman MD
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Search for more papers by this author
First published: 28 June 2023
No abstract is available for this article.
References
- 1Lucey BP, Liu H, Toedebusch CD, et al. Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS. Ann Neurol 2023; 94(1): 27–40.
